Amygdala activity after subchronic escitalopram administration in healthy volunteers: A pharmaco-functional magnetic resonance imaging study
Open accessThe DOI matches its Crossref record; 98 of the 101 references it cites were found in a registry or an index; none of the 76 sources its claims cite is checked for support yet.
Abstract
Background: Selective serotonin reuptake inhibitors (SSRIs) are used for the treatment of several conditions including anxiety disorders, but the basic neurobiology of serotonin function remains unclear. The amygdala and prefrontal cortex are strongly innervated by serotonergic projections and have been suggested to play an important role in anxiety expression. However, serotonergic function in behaviour and SSRI-mediated neurobiological changes remain incompletely understood. Aims: To investigate the neural correlates of subchronic antidepressant administration. Methods: We investigated whether the 2- to 3-week administration of a highly selective SSRI (escitalopram) would alter brain activation on a task robustly shown to recruit the bilateral amygdala and frontal cortices in a large healthy volunteer sample. Participants performed the task during a functional magnetic resonance imaging acquisition before ( n = 96) and after subchronic escitalopram ( n = 46, days of administration mean (SD) = 15.7 (2.70)) or placebo ( n = 40 days of administration mean (SD) = 16.2 (2.90)) self-administration. Results: Compared to placebo, we found an elevation in right amygdala activation to the task after escitalopram administration without significant changes in mood. This effect was not seen in the left amygdala, the dorsomedial region of interest, the subgenual anterior cingulate cortex or the right fusiform area. There were no significant changes in connectivity between the dorsomedial cortex and amygdala or the subgenual anterior cingulate cortex after escitalopram administration. Conclusions: To date, this most highly powered study of subchronic SSRI administration indicates that, contrary to effects often seen in patients with anxiety disorders, subchronic SSRI treatment may increase amygdala activation in healthy controls. This finding highlights important gaps in our understanding of the functional role of serotonin.
Overview
CoChat Summary
## TL;DR
In this double-blind pharmaco-fMRI study of healthy volunteers, 2–3 weeks of 10 mg/day escitalopram increased right amygdala activation during emotional face processing compared with placebo. The treatment did not significantly change left amygdala, sgACC, dorsal ROI, or rFFA activation, and did not alter dorsal ROI connectivity with amygdala or sgACC.
## Key findings
- At baseline, the task robustly activated the right amygdala, left amygdala, and rFFA, and deactivated the dorsal ROI and sgACC; for example, right amygdala activation had Cohen’s d = 1.17 and left amygdala d = 1.06.
- After subchronic treatment, right amygdala activation was higher in the escitalopram group than placebo in the average-parameter analysis (linear regression adjusting for age, sex, and baseline activation: p = 0.034, Cohen’s d = 0.52).
- There were no significant follow-up group differences in left amygdala (p = 0.13), dorsal ROI (p = 0.080), sgACC (p = 0.21), or rFFA (p = 0.19) activation.
- Connectivity findings at baseline were replicated, but follow-up connectivity did not differ between groups for the dorsal ROI with either amygdala seed or sgACC; the paper reports no significant group differences and notes equivalent AFNI analyses were also null.
## Methods
- Double-blind, repeated-measures, placebo-controlled design in healthy adults; participants completed fMRI before treatment and again after 12–23 days of self-administered escitalopram or placebo.
- Sample: 98 recruited; final baseline analysis n = 96. Follow-up included n = 46 escitalopram and n = 40 placebo in the abstract, with an intention-to-treat follow-up sample of total n = 86 reported later.
- Main task/analysis: an emotional face-processing block task (happy, fearful, neutral faces vs fixation cross) during fMRI; activation and generalized psychophysiological interaction connectivity were analyzed with ROI-based models in R and sensitivity analyses with AFNI small-volume correction.
## Limitations
- The paper states that compliance was assessed by self-report only, “so some non-adherence may have been present.”
- The authors state that results from healthy volunteers “may not generalise to patient populations.”
- Evident from the text: the follow-up sample was smaller than baseline because 8 participants withdrew or had technical issues and 2 were excluded for excessive motion, which limits power and comparability across timepoints.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 0 Not valid · 41 Not checked · 60 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“rFFA ( p = 0.19, Cohen's d = 0.33)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no significant group differences in the left amygdala ( p = 0.13, Cohen's d = 0.39)”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The results obtained with average regional activation parameters were corroborated by the small volume-corrected analyses in AFNI for the right and left amygdala (Figure 2(a)), dorsal ROI (Figure 2(b)), the sgACC (Figure 2(c)) and the rFFA (Supplemental Figure 2(a)).”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“dorsal ROI: reduced activation, p ⩽ 0.001, Cohen's d = 0.37”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“left amygdala: increased activation, p < 0.001, Cohen's d = 1.06”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
38 more claims
Create a free account to see all 101 claims and to verify the 76 references still open.
- The quote only partly states this claim. 2
- It may state two separate claims as one. 25
- Probably not a substantial claim. 43
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Connectivity
“Complementary small volume-corrected analyses in AFNI corroborated significant negative connectivity between the dorsal ROI and the sgACC only (see Supplement).”
§ Discussion
“Additionally, we found significant task-specific positive connectivity between the dorsal ROI and the sgACC which was not seen in our prior paper (Nord etal., 2019).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Activation
“Baseline. Consistent with our prior work, we found significant activation in all regions of interest at baseline (one-sample t -test, right amygdala: increased activation, p < 0.001, Cohen's d = 1.17, left amygdala: increased activation, p < 0.001, Cohen's d = 1.06, dorsal ROI: reduced activation, p ⩽ 0.001, Cohen's d = 0.37, sgACC:”
§ Discussion
“Previously, we found robust activation during emotion processing in the bilateral amygdala, dorsal ROI and rFFA, concomitant with reduced activation in the sgACC (Nord et al., 2017).”
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910 · cited 1×
“…completed the following questionnaires: The Beck Depression Inventory, Generalized Anxiety Disorder 7-item scale, The Patient Health Questionnaire 9-item scale and the State-Trait Anxiety Inventory (Beck et al., 1996; Kroenke et al., 2001; Spielberger et al., 1983; Spitzer et al., 2006).”
MethodA Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765 · cited 1×
“…completed the following questionnaires: The Beck Depression Inventory, Generalized Anxiety Disorder 7-item scale, The Patient Health Questionnaire 9-item scale and the State-Trait Anxiety Inventory (Beck et al., 1996; Kroenke et al., 2001; Spielberger et al., 1983; Spitzer et al., 2006).”
Method(1998) · PubMed · Cited by 10,216
fMRIPrep: A robust preprocessing pipeline for functional MRI
Esteban, O., Markiewicz, C. J., Blair, R. W., Moodie, C. A., Isik, A. I., Erramuzpe, A., Kent, J. D., Goncalves, M., DuPre, E., Snyder, M., et al. (2019) · Nature Methods · doi:10.1038/s41592-018-0235-4 · Cited by 3,905 · cited 1×
“Pre-processing of the fMRI data (slice time correction, motion correction, field map-based distortion correction, co-registration and normalisation) was performed with fMRIPrep version 20.2.7 (Esteban et al., 2018).”
MethodInfluentialEtkin, A., & Wager, T. D. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07030504 · Cited by 3,391 · cited 1×
“Both their activation and connectivity are associated with anxiety (Brühl et al., 2014; Carlisi and Robinson, 2018; Chavanne and Robinson, 2021; Etkin and Wager, 2007; Freitas-Ferrari et al., 2010; Goossen et al., 2019; Hattingh et al., 2012; Ipser et al., 2013; Kalisch and Gerlicher, 2014;…”
BackgroundThe amygdala: vigilance and emotion
Davis, M., & Whalen, P. J. (2001) · Molecular Psychiatry · doi:10.1038/sj.mp.4000812 · Cited by 2,882 · cited 1×
“The amygdala and prefrontal cortex have been frequently shown to be recruited during facial emotion-processing tasks (Davis and Whalen, 2000; Gangopadhyay et al., 2021; Phillips et al., 2003; Xu et al., 2016).”
BackgroundNeurobiology of emotion perception I: the neural basis of normal emotion perception
Phillips, M. L., Drevets, W. C., Rauch, S. L., & Lane, R. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00168-9 · Cited by 2,173 · cited 2×
“This result is also concordant with the literature, showing robust activation in the amygdala and prefrontal cortices during emotion processing (Fusar-Poli et al., 2009; Phillips et al., 2003).”
BackgroundResultInverted-U–Shaped Dopamine Actions on Human Working Memory and Cognitive Control
Cools, R., & D'Esposito, M. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.03.028 · Cited by 1,673 · cited 1×
“…systems, it has been shown that pharmacologically increasing dopaminergic function improves cognitive function in individuals with lower baseline dopamine levels, whereas it can impair cognitive task performance in people with higher baseline dopaminergic function (Cools and D’Esposito, 2011).”
BackgroundSubgroup analysis and other (mis)uses of baseline data in clinical trials
Assmann, S. F., Pocock, S. J., Enos, L. E., & Kasten, L. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02039-0 · Cited by 1,167 · cited 1×
“For the follow-up data, equivalent analyses were conducted with R’s lm function, including baseline activation or connectivity maps as a covariate of no interest, a method shown to have the largest power to estimate post-treatment effects (Assmann et al., 2000; Vickers, 2001).”
MethodKatzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090 · cited 1×
“However, it has been suggested that symptom reduction may start in the second week of antidepressant treatment (Baldwin et al., 2014; Katzman et al., 2014), which is equivalent to the mean time of antidepressant treatment in our ITT sample.”
BackgroundThe Maudsley Prescribing Guidelines in Psychiatry
Taylor, D. M., Barnes, T. R. E., & Young, A. H. (2021) · Wiley eBooks · doi:10.1002/9781119870203 · Cited by 988 · cited 1×
“This dose of escitalopram is recommended for the treatment of anxiety disorders (Taylor et al., 2021), based on the evidence of escitalopram’s efficacy superior to placebo in the treatment of generalised anxiety disorder, panic disorder and social anxiety disorder in the 5–20 mg range (Baldwin et…”
BackgroundKim, M. J., Loucks, R. A., Palmer, A. L., Brown, A. C., Solomon, K. M., Marchante, A. N., & Whalen, P. J. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.04.025 · Cited by 838 · cited 1×
“As amygdala hyperactivation is a robust finding in anxiety disorders (Kim et al., 2011; Kolesar et al., 2019; Pantazatos et al., 2013), it is plausible that this initial anxiogen-esis is a result of increases in anxiety-related brain activation (Chavanne and Robinson, 2021; Fox and Shackman, 2019).”
BackgroundVan Breukelen, G. J. P. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.02.007 · Cited by 765 · cited 1×
“…method was not used for primary inference as it was shown to be affected by measurement error and regression to the mean and to oppose the principles of appropriate randomisation, which was conducted in this study (Harrell, 2017; Knol et al., 2012; Roberts and Torgerson, 1999; Van Breukelen, 2006).”
MethodBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676 · cited 1×
“However, it has been suggested that symptom reduction may start in the second week of antidepressant treatment (Baldwin et al., 2014; Katzman et al., 2014), which is equivalent to the mean time of antidepressant treatment in our ITT sample.”
BackgroundVickers, A. J. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-6 · Cited by 559 · cited 1×
“For the follow-up data, equivalent analyses were conducted with R’s lm function, including baseline activation or connectivity maps as a covariate of no interest, a method shown to have the largest power to estimate post-treatment effects (Assmann et al., 2000; Vickers, 2001).”
MethodEfficacy of treatments for anxiety disorders: a meta-analysis
Bandelow, B., Reitt, M., Röver, C., Michaelis, S., Görlich, Y., & Wedekind, D. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000078 · Cited by 555 · cited 1×
“SSRIs can successfully treat persistent, pathological anxiety (Bandelow et al., 2015), indicating a key role for serotonin in anxiety processing.”
BackgroundSiegel, J. S., Power, J. D., Dubis, J. W., Vogel, A. C., Church, J. A., Schlaggar, B. L., & Petersen, S. E. (2014) · Human Brain Mapping · doi:10.1002/hbm.22307 · Cited by 546 · cited 1×
“Additionally, censoring of volumes exceeding framewise displacement of 1.3 mm (Siegel et al., 2014) was included in each model.”
MethodInfluentialAntidepressant Drug Treatment Modifies the Neural Processing of Nonconscious Threat Cues
Harmer, C. J., Mackay, C. E., Reid, C. B., Cowen, P. J., & Goodwin, G. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.10.015 · Cited by 450 · cited 3×
“…administering escitalopram or citalopram for a period sufficient for the drug to achieve a steady state (7–10 days) have been inconsistent (Arce et al., 2008; Harmer et al., 2006; Henry et al., 2013; Maron et al., 2016; McCabe et al., 2010; Norbury et al., 2009; Windischberger et al., 2010).”
BackgroundBrühl, A. B., Delsignore, A., Komossa, K., & Weidt, S. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.08.003 · Cited by 439 · cited 1×
“Both their activation and connectivity are associated with anxiety (Brühl et al., 2014; Carlisi and Robinson, 2018; Chavanne and Robinson, 2021; Etkin and Wager, 2007; Freitas-Ferrari et al., 2010; Goossen et al., 2019; Hattingh et al., 2012; Ipser et al., 2013; Kalisch and Gerlicher, 2014;…”
BackgroundMcTeague, L. M., Rosenberg, B. M., Lopez, J. W., Carreon, D. M., Huemer, J., Jiang, Y., Chick, C. F., Eickhoff, S. B., & Etkin, A. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.18111271 · Cited by 388 · cited 1×
“…(Brühl et al., 2014; Carlisi and Robinson, 2018; Chavanne and Robinson, 2021; Etkin and Wager, 2007; Freitas-Ferrari et al., 2010; Goossen et al., 2019; Hattingh et al., 2012; Ipser et al., 2013; Kalisch and Gerlicher, 2014; McTeague et al., 2020; Mochcovitch et al., 2014; Robinson et al., 2012).”
BackgroundMcCabe, C., Mishor, Z., Cowen, P. J., & Harmer, C. J. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.11.001 · Cited by 365 · cited 2×
“…administering escitalopram or citalopram for a period sufficient for the drug to achieve a steady state (7–10 days) have been inconsistent (Arce et al., 2008; Harmer et al., 2006; Henry et al., 2013; Maron et al., 2016; McCabe et al., 2010; Norbury et al., 2009; Windischberger et al., 2010).”
Fusar-Poli, P., Placentino, A., Carletti, F., Landi, P., Allen, P., Surguladze, S., Benedetti, F., Abbamonte, M., Gasparotti, R., Barale, F., et al. (2009) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0953 · Cited by 359 · cited 3×
“This result is also concordant with the literature, showing robust activation in the amygdala and prefrontal cortices during emotion processing (Fusar-Poli et al., 2009; Phillips et al., 2003).”
BackgroundMethodResultFurukawa, T. A., Cipriani, A., Cowen, P. J., Leucht, S., Egger, M., & Salanti, G. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30217-2 · Cited by 322 · cited 1×
“Thus, 10 mg was chosen to employ a dose of clinical efficacy, while limiting side effects which have been found to increase with higher dosages of antidepressants (Furukawa et al., 2019).”
MethodNeuroimaging in social anxiety disorder: a systematic review of the literature
Freitas-Ferrari, M. C., Hallak, J. E. C., Trzesniak, C., Filho, A. S., Machado-de-Sousa, J. P., Chagas, M. H. N., Nardi, A. E., & Crippa, J. A. S. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.02.028 · Cited by 298 · cited 1×
“…and connectivity are associated with anxiety (Brühl et al., 2014; Carlisi and Robinson, 2018; Chavanne and Robinson, 2021; Etkin and Wager, 2007; Freitas-Ferrari et al., 2010; Goossen et al., 2019; Hattingh et al., 2012; Ipser et al., 2013; Kalisch and Gerlicher, 2014; McTeague et al., 2020;…”
BackgroundUnderstanding controlled trials: Baseline imbalance in randomised controlled trials
Roberts, C., & Torgerson, D. J. (1999) · BMJ · doi:10.1136/bmj.319.7203.185 · Cited by 286 · cited 1×
“…method was not used for primary inference as it was shown to be affected by measurement error and regression to the mean and to oppose the principles of appropriate randomisation, which was conducted in this study (Harrell, 2017; Knol et al., 2012; Roberts and Torgerson, 1999; Van Breukelen, 2006).”
MethodDel-Ben, C. M., Deakin, J. F. W., Mckie, S., Delvai, N. A., Williams, S. R., Elliott, R., Dolan, M., & Anderson, I. M. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300728 · Cited by 260 · cited 1×
“…activation during emotion processing, but other studies using such paradigm found an increase or no change in amygdala activation (decrease: Del-Ben et al., 2005; Grady et al., 2013; Harmer et al., 2006; Murphy et al., 2009; Windischberger et al., 2010; increase: Bigos et al., 2008;…”
MethodThe Clinical Pharmacokinetics of Escitalopram
Rao, N. (2007) · Clinical Pharmacokinetics · doi:10.2165/00003088-200746040-00002 · Cited by 256 · cited 2×
“…days necessary to achieve a steady state of the pharmacology, but less than the 4 weeks shown to be clinically effective (Jakubovski et al., 2019; Rao, 2007) found reduced, increased or no changes in amygdala activation during emotional face processing in healthy volunteers (reduced: Harmer et…”
BackgroundMethodEffect of a single dose of citalopram on amygdala response to emotional faces
Murphy, S. E., Norbury, R., O'Sullivan, U., Cowen, P. J., & Harmer, C. J. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.056093 · Cited by 255 · cited 3×
“…administering escitalopram or citalopram for a period sufficient for the drug to achieve a steady state (7–10 days) have been inconsistent (Arce et al., 2008; Harmer et al., 2006; Henry et al., 2013; Maron et al., 2016; McCabe et al., 2010; Norbury et al., 2009; Windischberger et al., 2010).”
BackgroundMethodChavanne, A. V., & Robinson, O. J. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.19111153 · Cited by 252 · cited 2×
“As amygdala hyperactivation is a robust finding in anxiety disorders (Kim et al., 2011; Kolesar et al., 2019; Pantazatos et al., 2013), it is plausible that this initial anxiogen-esis is a result of increases in anxiety-related brain activation (Chavanne and Robinson, 2021; Fox and Shackman, 2019).”
BackgroundSelf-citationBurghardt, N. S., Sullivan, G. M., McEwen, B. S., Gorman, J. M., & LeDoux, J. E. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.02.029 · Cited by 246 · cited 2×
“…SSRI administration in rodents was found to increase anxiety-related behaviour, whereas chronic administration was reported to reduce it (Bocchio et al., 2016; Burghardt et al., 2004; Ravinder et al., 2013), mirroring findings in human psychophysiological research (Grillon et al., 2007, 2009).”
ResultPrefrontal–amygdala circuits in social decision-making
Gangopadhyay, P., Chawla, M., Dal Monte, O., & Chang, S. W. C. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00738-9 · Cited by 241 · cited 2×
“The amygdala and prefrontal cortex have been frequently shown to be recruited during facial emotion-processing tasks (Davis and Whalen, 2000; Gangopadhyay et al., 2021; Phillips et al., 2003; Xu et al., 2016).”
BackgroundMochcovitch, M. D., da Rocha Freire, R. C., Garcia, R. F., & Nardi, A. E. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.06.041 · Cited by 206 · cited 1×
“…(Brühl et al., 2014; Carlisi and Robinson, 2018; Chavanne and Robinson, 2021; Etkin and Wager, 2007; Freitas-Ferrari et al., 2010; Goossen et al., 2019; Hattingh et al., 2012; Ipser et al., 2013; Kalisch and Gerlicher, 2014; McTeague et al., 2020; Mochcovitch et al., 2014; Robinson et al., 2012).”
BackgroundPuglisi-Allegra, S., & Andolina, D. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.052 · Cited by 203 · cited 1×
“Serotonergic neurotransmission mediates numerous brain functions, from mood to cognition (Duerler et al., 2022; Puglisi-Allegra and Andolina, 2015), and its pharmacological manipulation is used in the treatment of multiple conditions, from anxiety disorders to chronic pain.”
BackgroundSerotonin, Amygdala and Fear: Assembling the Puzzle
Bocchio, M., McHugh, S. B., Bannerman, D. M., Sharp, T., & Capogna, M. (2016) · Frontiers in Neural Circuits · doi:10.3389/fncir.2016.00024 · Cited by 202 · cited 3×
“Both regions receive strong serotonergic projections (Parent and Descarries, 2020), and modulation of serotonin in these regions alters both anxiety (Bocchio et al., 2016) and aversive processing (Duerler et al., 2022; Garcia-Garcia and Soiza-Reilly, 2019).”
BackgroundEscitalopram effects on insula and amygdala BOLD activation during emotional processing
Arce, E., Simmons, A. N., Lovero, K. L., Stein, M. B., & Paulus, M. P. (2008) · Psychopharmacology · doi:10.1007/s00213-007-1004-8 · Cited by 198 · cited 4×
“…amygdala activation during emotional face processing is in contrast to the results of three previous fMRI studies with subchronic (2– 3 weeks) escitalopram administration, which found no differences in amygdala activation to the task (Arce et al., 2008; Henry et al., 2013; Simmons et al., 2009).”
BackgroundResultInfluentialRobinson, O. J., Charney, D. R., Overstreet, C., Vytal, K., & Grillon, C. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.096 · Cited by 196 · cited 1×
“…(Brühl et al., 2014; Carlisi and Robinson, 2018; Chavanne and Robinson, 2021; Etkin and Wager, 2007; Freitas-Ferrari et al., 2010; Goossen et al., 2019; Hattingh et al., 2012; Ipser et al., 2013; Kalisch and Gerlicher, 2014; McTeague et al., 2020; Mochcovitch et al., 2014; Robinson et al., 2012).”
BackgroundSelf-citationAmygdala Circuit Substrates for Stress Adaptation and Adversity
Zhang, W.-H., Zhang, J.-Y., Holmes, A., & Pan, B.-X. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.12.026 · Cited by 196 · cited 1×
“The prefrontal cortex can exert regulatory control over the amygdala during emotion processing (Gangopadhyay et al., 2021; Zhang et al., 2021), and this connectivity has also been shown to be elevated by SSRIs (Outhred et al., 2015; Sladky et al., 2015).”
BackgroundFox, A. S., & Shackman, A. J. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2017.11.056 · Cited by 194 · cited 1×
“As amygdala hyperactivation is a robust finding in anxiety disorders (Kim et al., 2011; Kolesar et al., 2019; Pantazatos et al., 2013), it is plausible that this initial anxiogen-esis is a result of increases in anxiety-related brain activation (Chavanne and Robinson, 2021; Fox and Shackman, 2019).”
BackgroundGold, A. L., Morey, R. A., & McCarthy, G. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.030 · Cited by 192 · cited 1×
“The former result also replicates other studies, which also found task-specific increases in amygdala connectivity with the dorsomedial prefrontal cortex during emotion-related paradigms (Gold et al., 2015; Vytal et al., 2014), albeit not all (Outhred et al., 2015).”
ResultAntidepressant-induced jitteriness/anxiety syndrome: systematic review
Sinclair, L. I., Christmas, D. M., Hood, S. D., Potokar, J. P., Robertson, A., Isaac, A., Srivastava, S., Nutt, D. J., & Davies, S. J. C. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.107.048371 · Cited by 181 · cited 1×
“…be consistent with the clinically recognised phenomenon of an increase in subjective anxiety in the initial weeks of SSRI administration (Burghardt et al., 2004; Gollan et al., 2012; National Institute for Health and Care Excellence, 2020; Sinclair et al., 2009; Westenberg and Den Boer, 1989).”
Modulating the Neuromodulators: Dopamine, Serotonin, and the Endocannabinoid System
Peters, K. Z., Cheer, J. F., & Tonini, R. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2021.02.001 · Cited by 168 · cited 1×
“Serotonergic projections innervate numerous brain regions, modulating multiple brain functions such as anxiety (Parent and Descarries, 2020; Peters et al., 2021).”
BackgroundAcute 5-HT Reuptake Blockade Potentiates Human Amygdala Reactivity
Bigos, K. L., Pollock, B. G., Aizenstein, H. J., Fisher, P. M., Bies, R. R., & Hariri, A. R. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.52 · Cited by 164 · cited 1×
“…an increase or no change in amygdala activation (decrease: Del-Ben et al., 2005; Grady et al., 2013; Harmer et al., 2006; Murphy et al., 2009; Windischberger et al., 2010; increase: Bigos et al., 2008; Selvaraj et al., 2017; no change: Brühl et al., 2009; Hornboll et al., 2018; Klomp et al., 2013).”
BackgroundGrillon, C., Levenson, J., & Pine, D. S. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301204 · Cited by 162 · cited 2×
“…SSRI administration in rodents was found to increase anxiety-related behaviour, whereas chronic administration was reported to reduce it (Bocchio et al., 2016; Burghardt et al., 2004; Ravinder et al., 2013), mirroring findings in human psychophysiological research (Grillon et al., 2007, 2009).”
BackgroundResultRobinson, O. J., Krimsky, M., Lieberman, L., Allen, P., Vytal, K., & Grillon, C. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70305-0 · Cited by 155 · cited 1×
“…results, some showing increases, some reductions and some unchanged amygdala connectivity with the dorsal or dorsomedial prefrontal cortex (increases: Reinecke et al., 2015; Robinson et al., 2014; reductions: Kaldewaij et al., 2019; unchanged: Böhnlein et al., 2021; Duval et al., 2020).”
BackgroundSelf-citationKolesar, T. A., Bilevicius, E., Wilson, A. D., & Kornelsen, J. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.102016 · Cited by 154 · cited 1×
“As amygdala hyperactivation is a robust finding in anxiety disorders (Kim et al., 2011; Kolesar et al., 2019; Pantazatos et al., 2013), it is plausible that this initial anxiogen-esis is a result of increases in anxiety-related brain activation (Chavanne and Robinson, 2021; Fox and Shackman, 2019).”
BackgroundMeta-analysis of functional brain imaging in specific phobia
Ipser, J. C., Singh, L., & Stein, D. J. (2013) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12055 · Cited by 142 · cited 1×
“…(Brühl et al., 2014; Carlisi and Robinson, 2018; Chavanne and Robinson, 2021; Etkin and Wager, 2007; Freitas-Ferrari et al., 2010; Goossen et al., 2019; Hattingh et al., 2012; Ipser et al., 2013; Kalisch and Gerlicher, 2014; McTeague et al., 2020; Mochcovitch et al., 2014; Robinson et al., 2012).”
BackgroundStahl, S. M., Gergel, I., & Li, D. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1107 · Cited by 139 · cited 1×
“…disorders (Taylor et al., 2021), based on the evidence of escitalopram’s efficacy superior to placebo in the treatment of generalised anxiety disorder, panic disorder and social anxiety disorder in the 5–20 mg range (Baldwin et al., 2016; Blanco et al., 2013; Kong et al., 2020; Stahl and Li, 2003).”
BackgroundIs the statistic value all we should care about in neuroimaging?
Chen, G., Taylor, P. A., & Cox, R. W. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2016.09.066 · Cited by 139 · cited 1×
“…3dTstat and 3dcalc from the Analysis of Functional Neuroimages (AFNI) software were used for fMRI series smoothing (Gaussian kernel: 6 mm full width at half maximum) and grand mean scaling (Chen et al., 2017) within an Montreal Neurological Institute (MNI) space-specific grey matter mask.”
MethodSystematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131 · cited 2×
“…period (over the 10 days necessary to achieve a steady state of the pharmacology, but less than the 4 weeks shown to be clinically effective (Jakubovski et al., 2019; Rao, 2007) found reduced, increased or no changes in amygdala activation during emotional face processing in healthy…”
BackgroundHattingh, C. J., Ipser, J., Tromp, S. A., Syal, S., Lochner, C., Brooks, S. J., & Stein, D. J. (2013) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2012.00347 · Cited by 129 · cited 1×
“…(Brühl et al., 2014; Carlisi and Robinson, 2018; Chavanne and Robinson, 2021; Etkin and Wager, 2007; Freitas-Ferrari et al., 2010; Goossen et al., 2019; Hattingh et al., 2012; Ipser et al., 2013; Kalisch and Gerlicher, 2014; McTeague et al., 2020; Mochcovitch et al., 2014; Robinson et al., 2012).”
BackgroundBurghardt, N. S., & Bauer, E. P. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.05.050 · Cited by 125 · cited 3×
“…auto-receptors on DRN neurons, which may initially reduce their firing during temporarily increased synaptic serotonin levels (Commons, 2020; Sargin et al., 2019), but expression of which is then downregulated with long-term SSRI administration (Burghardt and Bauer, 2013; Di Giovanni et al., 2020).”
BackgroundKalisch, R., & Gerlicher, A. M. V. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.02.002 · Cited by 118 · cited 1×
“…(Brühl et al., 2014; Carlisi and Robinson, 2018; Chavanne and Robinson, 2021; Etkin and Wager, 2007; Freitas-Ferrari et al., 2010; Goossen et al., 2019; Hattingh et al., 2012; Ipser et al., 2013; Kalisch and Gerlicher, 2014; McTeague et al., 2020; Mochcovitch et al., 2014; Robinson et al., 2012).”
BackgroundWindischberger, C., Lanzenberger, R., Holik, A., Spindelegger, C., Stein, P., Moser, U., Gerstl, F., Fink, M., Moser, E., & Kasper, S. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2009.10.013 · Cited by 114 · cited 4×
“…found an increase or no change in amygdala activation (decrease: Del-Ben et al., 2005; Grady et al., 2013; Harmer et al., 2006; Murphy et al., 2009; Windischberger et al., 2010; increase: Bigos et al., 2008; Selvaraj et al., 2017; no change: Brühl et al., 2009; Hornboll et al., 2018; Klomp et al.,…”
BackgroundResultInfluentialShort-term antidepressant treatment modulates amygdala response to happy faces
Norbury, R., Taylor, M. J., Selvaraj, S., Murphy, S. E., Harmer, C. J., & Cowen, P. J. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1597-1 · Cited by 109 · cited 2×
“…administering escitalopram or citalopram for a period sufficient for the drug to achieve a steady state (7–10 days) have been inconsistent (Arce et al., 2008; Harmer et al., 2006; Henry et al., 2013; Maron et al., 2016; McCabe et al., 2010; Norbury et al., 2009; Windischberger et al., 2010).”
BackgroundVytal, K. E., Overstreet, C. M., Charney, D. R., Robinson, O. J., & Grillon, C. (2014) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.130145 · Cited by 99 · cited 1×
“The former result also replicates other studies, which also found task-specific increases in amygdala connectivity with the dorsomedial prefrontal cortex during emotion-related paradigms (Gold et al., 2015; Vytal et al., 2014), albeit not all (Outhred et al., 2015).”
ResultSelf-citationThe evidence-based pharmacotherapy of social anxiety disorder
Blanco, C., Bragdon, L. B., Schneier, F. R., & Liebowitz, M. R. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000119 · Cited by 99 · cited 1×
“…disorders (Taylor et al., 2021), based on the evidence of escitalopram’s efficacy superior to placebo in the treatment of generalised anxiety disorder, panic disorder and social anxiety disorder in the 5–20 mg range (Baldwin et al., 2016; Blanco et al., 2013; Kong et al., 2020; Stahl and Li, 2003).”
BackgroundUnreliability of putative fMRI biomarkers during emotional face processing
Nord, C. L., Gray, A., Charpentier, C. J., Robinson, O. J., & Roiser, J. P. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.05.024 · Cited by 94 · cited 11×
“In our previous research in healthy volunteers, we have used such task to show robust activation within the bilateral amygdala and the right fusiform area (rFFA), and deactivation of the subgenual anterior cingulate cortex (sgACC) (Nord et al., 2017).”
BackgroundMethodInfluentialSelf-citationGrillon, C., Chavis, C., Covington, M. F., & Pine, D. S. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.141 · Cited by 88 · cited 1×
“Specifically, in healthy human volunteers, a single dose of citalopram elevates anxiety-potentiated startle (Grillon et al., 2007), while a 2-week administration of the same drug has the opposite effect: reduced anxiety-potentiated startle (Grillon et al., 2009).”
BackgroundSimmons, A. N., Arce, E., Lovero, K. L., Stein, M. B., & Paulus, M. P. (2009) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990149 · Cited by 80 · cited 3×
“…amygdala activation during emotional face processing is in contrast to the results of three previous fMRI studies with subchronic (2– 3 weeks) escitalopram administration, which found no differences in amygdala activation to the task (Arce et al., 2008; Henry et al., 2013; Simmons et al., 2009).”
BackgroundResultPantazatos, S. P., Talati, A., Schneier, F. R., & Hirsch, J. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.211 · Cited by 73 · cited 1×
“As amygdala hyperactivation is a robust finding in anxiety disorders (Kim et al., 2011; Kolesar et al., 2019; Pantazatos et al., 2013), it is plausible that this initial anxiogen-esis is a result of increases in anxiety-related brain activation (Chavanne and Robinson, 2021; Fox and Shackman, 2019).”
BackgroundSerotonergic and Noradrenergic Modulation of Emotion Processing by Single Dose Antidepressants
Brühl, A. B., Kaffenberger, T., & Herwig, U. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.159 · Cited by 73 · cited 1×
“…an increase or no change in amygdala activation (decrease: Del-Ben et al., 2005; Grady et al., 2013; Harmer et al., 2006; Murphy et al., 2009; Windischberger et al., 2010; increase: Bigos et al., 2008; Selvaraj et al., 2017; no change: Brühl et al., 2009; Hornboll et al., 2018; Klomp et al., 2013).”
BackgroundOuthred, T., Hawkshead, B. E., Wager, T. D., Das, P., Malhi, G. S., & Kemp, A. H. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.07.010 · Cited by 72
Xu, M., Xu, G., & Yang, Y. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00220 · Cited by 71 · cited 1×
“The amygdala and prefrontal cortex have been frequently shown to be recruited during facial emotion-processing tasks (Davis and Whalen, 2000; Gangopadhyay et al., 2021; Phillips et al., 2003; Xu et al., 2016).”
BackgroundRobinson, O. J., Overstreet, C., Allen, P. S., Letkiewicz, A., Vytal, K., Pine, D. S., & Grillon, C. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.03.075 · Cited by 64 · cited 1×
“Moreover, acute depletion of the serotonin precursor tryptophan was found to increase anxiety-related amygdala-prefrontal connectivity (Robinson et al., 2013).”
BackgroundSelf-citationReview: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)
Davidson, Jr., Zhang, W., Connor, K., Ji, J., Jobson, K., Lecrubier, Y., McFarlane, A., Newport, D., Nutt, D., Osser, D., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108096505 · Cited by 63
Ravinder, S., Burghardt, N. S., Brodsky, R., Bauer, E. P., & Chattarji, S. (2013) · Translational Psychiatry · doi:10.1038/tp.2012.137 · Cited by 59 · cited 1×
“…SSRI administration in rodents was found to increase anxiety-related behaviour, whereas chronic administration was reported to reduce it (Bocchio et al., 2016; Burghardt et al., 2004; Ravinder et al., 2013), mirroring findings in human psychophysiological research (Grillon et al., 2007, 2009).”
ResultSelvaraj, S., Walker, C., Arnone, D., Cao, B., Faulkner, P., Cowen, P. J., Roiser, J. P., & Howes, O. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.166 · Cited by 58 · cited 1×
“…an increase or no change in amygdala activation (decrease: Del-Ben et al., 2005; Grady et al., 2013; Harmer et al., 2006; Murphy et al., 2009; Windischberger et al., 2010; increase: Bigos et al., 2008; Selvaraj et al., 2017; no change: Brühl et al., 2009; Hornboll et al., 2018; Klomp et al., 2013).”
BackgroundReinecke, A., Filippini, N., Berna, C., Western, D. G., Hanson, B., Cooper, M. J., Taggart, P., & Harmer, C. J. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.160 · Cited by 54 · cited 1×
“…results, some showing increases, some reductions and some unchanged amygdala connectivity with the dorsal or dorsomedial prefrontal cortex (increases: Reinecke et al., 2015; Robinson et al., 2014; reductions: Kaldewaij et al., 2019; unchanged: Böhnlein et al., 2021; Duval et al., 2020).”
BackgroundSargin, D., Jeoung, H.-S., Goodfellow, N. M., & Lambe, E. K. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00073 · Cited by 54 · cited 1×
“…5-HT1A auto-receptors on DRN neurons, which may initially reduce their firing during temporarily increased synaptic serotonin levels (Commons, 2020; Sargin et al., 2019), but expression of which is then downregulated with long-term SSRI administration (Burghardt and Bauer, 2013; Di Giovanni et…”
BackgroundA neurobiological perspective on social influence: Serotonin and social adaptation
Duerler, P., Vollenweider, F. X., & Preller, K. H. (2022) · Journal of Neurochemistry · doi:10.1111/jnc.15607 · Cited by 53 · cited 2×
“Both regions receive strong serotonergic projections (Parent and Descarries, 2020), and modulation of serotonin in these regions alters both anxiety (Bocchio et al., 2016) and aversive processing (Duerler et al., 2022; Garcia-Garcia and Soiza-Reilly, 2019).”
BackgroundGrady, C. L., Siebner, H. R., Hornbøll, B., Macoveanu, J., Paulson, O. B., & Knudsen, G. M. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.06.003 · Cited by 51 · cited 1×
“…emotion processing, but other studies using such paradigm found an increase or no change in amygdala activation (decrease: Del-Ben et al., 2005; Grady et al., 2013; Harmer et al., 2006; Murphy et al., 2009; Windischberger et al., 2010; increase: Bigos et al., 2008; Selvaraj et al., 2017; no…”
MethodA review of neuroimaging studies in generalized anxiety disorder: “So where do we stand?”
Goossen, B., van der Starre, J., & van der Heiden, C. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02024-w · Cited by 48 · cited 1×
“…with anxiety (Brühl et al., 2014; Carlisi and Robinson, 2018; Chavanne and Robinson, 2021; Etkin and Wager, 2007; Freitas-Ferrari et al., 2010; Goossen et al., 2019; Hattingh et al., 2012; Ipser et al., 2013; Kalisch and Gerlicher, 2014; McTeague et al., 2020; Mochcovitch et al., 2014;…”
BackgroundSladky, R., Spies, M., Hoffmann, A., Kranz, G. S., Hummer, A., Gryglewski, G., Lanzenberger, R. R., Windischberger, C., & Kasper, S. F. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.12.044 · Cited by 45 · cited 1×
“The prefrontal cortex can exert regulatory control over the amygdala during emotion processing (Gangopadhyay et al., 2021; Zhang et al., 2021), and this connectivity has also been shown to be elevated by SSRIs (Outhred et al., 2015; Sladky et al., 2015).”
BackgroundKong, W., Deng, H., Wan, J., Zhou, Y., Zhou, Y., Song, B., & Wang, X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.580858 · Cited by 44 · cited 1×
“…disorders (Taylor et al., 2021), based on the evidence of escitalopram’s efficacy superior to placebo in the treatment of generalised anxiety disorder, panic disorder and social anxiety disorder in the 5–20 mg range (Baldwin et al., 2016; Blanco et al., 2013; Kong et al., 2020; Stahl and Li, 2003).”
BackgroundKnol, M., Groenwold, R., & Grobbee, D. (2012) · European Journal of Preventive Cardiology · doi:10.1177/1741826711421688 · Cited by 41 · cited 1×
“…method was not used for primary inference as it was shown to be affected by measurement error and regression to the mean and to oppose the principles of appropriate randomisation, which was conducted in this study (Harrell, 2017; Knol et al., 2012; Roberts and Torgerson, 1999; Van Breukelen, 2006).”
MethodCarlisi, C. O., & Robinson, O. J. (2018) · Brain and Neuroscience Advances · doi:10.1177/2398212818774223 · Cited by 41 · cited 1×
“Both their activation and connectivity are associated with anxiety (Brühl et al., 2014; Carlisi and Robinson, 2018; Chavanne and Robinson, 2021; Etkin and Wager, 2007; Freitas-Ferrari et al., 2010; Goossen et al., 2019; Hattingh et al., 2012; Ipser et al., 2013; Kalisch and Gerlicher, 2014;…”
BackgroundSelf-citationDuval, E. R., Sheynin, J., King, A. P. J., Phan, K. L., Simon, N. M., Martis, B., Porter, K. E., Norman, S. B., Liberzon, I., & Rauch, S. A. M. (2020) · Depression and Anxiety · doi:10.1002/da.23022 · Cited by 38 · cited 2×
“Similarly, no alterations in dmPFC or vmPFC connectivity with the amygdala were found in anxiety disorders (dmPFC: Cui et al., 2022; Duval et al., 2020; vmPFC: De la Peña-Arteaga et al., 2022).”
BackgroundGollan, J., Fava, M., Kurian, B. T., Wisniewski, S., Rush, A., Daly, E., Miyahara, S., & Trivedi, M. H. (2011) · Depression and Anxiety · doi:10.1002/da.20917 · Cited by 36
Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo
Baldwin, D. S., Asakura, S., Koyama, T., Hayano, T., Hagino, A., Reines, E., & Larsen, K. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.02.013 · Cited by 36 · cited 1×
“…disorders (Taylor et al., 2021), based on the evidence of escitalopram’s efficacy superior to placebo in the treatment of generalised anxiety disorder, panic disorder and social anxiety disorder in the 5–20 mg range (Baldwin et al., 2016; Blanco et al., 2013; Kong et al., 2020; Stahl and Li, 2003).”
BackgroundO'Nions, E. J. P., Dolan, R. J., & Roiser, J. P. (2011) · Journal of Cognitive Neuroscience · doi:10.1162/jocn_a_00055 · Cited by 30
Serotonin-Influencing Drugs in the Treatment of Panic Disorder
Westenberg, H. G. M., & den Boer, J. A. (2010) · Psychopathology · doi:10.1159/000284628 · Cited by 29 · cited 1×
“…be consistent with the clinically recognised phenomenon of an increase in subjective anxiety in the initial weeks of SSRI administration (Burghardt et al., 2004; Gollan et al., 2012; National Institute for Health and Care Excellence, 2020; Sinclair et al., 2009; Westenberg and Den Boer, 1989).”
BackgroundEffect of short-term escitalopram treatment on neural activation during emotional processing
Maron, E., Wall, M. B., Norbury, R., Godlewska, B. R., Terbeck, S., Cowen, P. J., Matthews, P. M., & Nutt, D. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115620462 · Cited by 24
Facilitation of emotion regulation with a single dose of escitalopram: A randomized fMRI study
Outhred, T., Das, P., Felmingham, K. L., Bryant, R. A., Nathan, P. J., Malhi, G. S., & Kemp, A. H. (2015) · Psychiatry Research: Neuroimaging · doi:10.1016/j.pscychresns.2015.07.018 · Cited by 21 · cited 7×
“Thus, both activation and connectivity between these two areas may be altered by SSRIs to elicit their anxiolytic function.”
BackgroundResultInfluentialKlomp, A., van Wingen, G. A., de Ruiter, M. B., Caan, M. W. A., Denys, D. A. J. P., & Reneman, L. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.03.002 · Cited by 20 · cited 1×
“…an increase or no change in amygdala activation (decrease: Del-Ben et al., 2005; Grady et al., 2013; Harmer et al., 2006; Murphy et al., 2009; Windischberger et al., 2010; increase: Bigos et al., 2008; Selvaraj et al., 2017; no change: Brühl et al., 2009; Hornboll et al., 2018; Klomp et al., 2013).”
BackgroundNeural processing of emotional facial stimuli in specific phobia: An fMRI study
Böhnlein, J., Leehr, E. J., Roesmann, K., Sappelt, T., Platte, O., Grotegerd, D., Sindermann, L., Repple, J., Opel, N., Meinert, S., et al. (2021) · Depression and Anxiety · doi:10.1002/da.23191 · Cited by 18 · cited 1×
“…results, some showing increases, some reductions and some unchanged amygdala connectivity with the dorsal or dorsomedial prefrontal cortex (increases: Reinecke et al., 2015; Robinson et al., 2014; reductions: Kaldewaij et al., 2019; unchanged: Böhnlein et al., 2021; Duval et al., 2020).”
BackgroundReed, M. B., Klöbl, M., Godbersen, G. M., Handschuh, P. A., Ritter, V., Spurny‐Dworak, B., Unterholzner, J., Kraus, C., Gryglewski, G., Winkler, D., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.118887 · Cited by 18 · cited 1×
“This result is less easily interpretable as to our knowledge, there has only been one study investigating SSRI-induced changes in brain connectivity during an emotion-processing task with the gPPI approach, which did not use any of our regions of interest (Reed et al., 2022).”
ResultCui, Q., Chen, Y., Tang, Q., Sheng, W., Li, D., Zeng, Y., Jiang, K., He, Z., & Chen, H. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110595 · Cited by 18 · cited 1×
“Similarly, no alterations in dmPFC or vmPFC connectivity with the amygdala were found in anxiety disorders (dmPFC: Cui et al., 2022; Duval et al., 2020; vmPFC: De la Peña-Arteaga et al., 2022).”
BackgroundReliability of fronto–amygdala coupling during emotional face processing
Nord, C., Gray, A., Robinson, O., & Roiser, J. (2019) · Brain Sciences · doi:10.3390/brainsci9040089 · Cited by 17 · cited 11×
“Our primary analysis was done in R 4.2.2., adapting the same analysis approach as that taken in the publications we aimed to replicate (Nord et al., 2017, 2019).”
BackgroundMethodInfluentialSelf-citationHornbøll, B., Macoveanu, J., Nejad, A. B., Rowe, J. B., Elliott, R., Knudsen, G. M., Siebner, H. R., & Paulson, O. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-36350-y · Cited by 16 · cited 1×
“…an increase or no change in amygdala activation (decrease: Del-Ben et al., 2005; Grady et al., 2013; Harmer et al., 2006; Murphy et al., 2009; Windischberger et al., 2010; increase: Bigos et al., 2008; Selvaraj et al., 2017; no change: Brühl et al., 2009; Hornboll et al., 2018; Klomp et al., 2013).”
BackgroundMendez, E. M., Mills, J. A., Suresh, V., Stimpfl, J. N., & Strawn, J. R. (2024) · CNS Spectrums · doi:10.1017/s1092852924000142 · Cited by 15 · cited 1×
“On the one hand, evidence suggests an average of 4 weeks of treatment is required to alter mood in clinical populations (Jakubovski et al., 2019; Mendez et al., 2024).”
BackgroundKaldewaij, R., Reinecke, A., & Harmer, C. J. (2019) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2019.07.002 · Cited by 14 · cited 1×
“…results, some showing increases, some reductions and some unchanged amygdala connectivity with the dorsal or dorsomedial prefrontal cortex (increases: Reinecke et al., 2015; Robinson et al., 2014; reductions: Kaldewaij et al., 2019; unchanged: Böhnlein et al., 2021; Duval et al., 2020).”
BackgroundAn fMRI study of cognitive regulation of reward processing in generalized anxiety disorder (GAD)
la Peña‐Arteaga, V. D., Fernández-Rodríguez, M., Moreira, P. S., Abreu, T., Portugal‐Nunes, C., Soriano‐Mas, C., Picó‐Pérez, M., Sousa, N., Ferreira, S., & Morgado, P. F. (2022) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2022.111493 · Cited by 14 · cited 1×
“Similarly, no alterations in dmPFC or vmPFC connectivity with the amygdala were found in anxiety disorders (dmPFC: Cui et al., 2022; Duval et al., 2020; vmPFC: De la Peña-Arteaga et al., 2022).”
BackgroundHenry, M., Lauriat, T. L., Lowen, S. B., Churchill, J. H., Hodgkinson, C. A., Goldman, D. A., & Renshaw, P. F. (2013) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2013.05.008 · Cited by 11 · cited 3×
“…amygdala activation during emotional face processing is in contrast to the results of three previous fMRI studies with subchronic (2– 3 weeks) escitalopram administration, which found no differences in amygdala activation to the task (Arce et al., 2008; Henry et al., 2013; Simmons et al., 2009).”
BackgroundResultSerotonergic control of excitability: from neuron to networks
Giovanni, G. D., Chagraoui, A., Bharatiya, R., & Deurwaerdère, P. D. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00010-4 · Cited by 11 · cited 1×
“…auto-receptors on DRN neurons, which may initially reduce their firing during temporarily increased synaptic serotonin levels (Commons, 2020; Sargin et al., 2019), but expression of which is then downregulated with long-term SSRI administration (Burghardt and Bauer, 2013; Di Giovanni et al., 2020).”
BackgroundSerotonin system function, organization, and feedback
Commons, K. G. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00003-7 · Cited by 9 · cited 1×
“…presynaptic 5-HT1A auto-receptors on DRN neurons, which may initially reduce their firing during temporarily increased synaptic serotonin levels (Commons, 2020; Sargin et al., 2019), but expression of which is then downregulated with long-term SSRI administration (Burghardt and Bauer, 2013; Di…”
BackgroundUltrastructure of the serotonin innervation in mammalian central nervous system
Parent, M., & Descarries, L. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00004-9 · Cited by 7
Serotonin Subsystems Modulate Diverse and Opposite Behavioral Functions
Garcia‐García, Á. L., & Soiza‐Reilly, M. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00534 · Cited by 6
Research works printed but not linked: 2
- Beck AT, Steer RA, Brown GK (1996) Manual for the Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation.
- Spielberger CD, Gorsuch RL, Lushene R, et al. (1983) Manual for the State-Trait Anxiety Scale. Washington, DC Consulting Psychologists Press.
Cited by
Navarro-Nolasco, D. A., Chi-Castañeda, D., López‐Meraz, M. L., Beltrán‐Parrazal, L., & Morgado‐Valle, C. (2025) · BMC Psychology · doi:10.1186/s40359-025-02449-x · Cited by 37
“Complementary evidence shows that escitalopram administration modulates dmPFC activity during emotional face-processing tasks, although the effects vary based on baseline neural function and participant health [72].”
A cognitive neuroscience approach to understanding aggression and its treatment
Blair, J., Habel, U., Votinov, M., Wagels, L., & Denson, T. F. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106386 · Cited by 11
Lukow, P. B., Lowther, M., Pike, A. C., Yamamori, Y., Chavanne, A. V., Gormley, S., Aylward, J., Vera, C. E., McCloud, T. L., Goble, T., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120682 · Cited by 2
Self-citation
Metadata
- Authors
- Lukow, P. B., Lowther, M., Pike, A. C., Yamamori, Y., Chavanne, A. V., Gormley, S., Aylward, J., McCloud, T., Goble, T., Rodriguez-Sanchez, J., Tuominen, E. W., Buehler, S. K., Kirk, P., & Robinson, O. J.
- Affiliations
- University College London (GB)
- École Normale Supérieure Paris-Saclay (FR)
- National Institute of Mental Health (US)
- Corresponding author
- Lukow, Paulina B
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2024-10-04
- Volume
- 38
- Issue
- 12
- Pages
- 1071-1082
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- PMC
- PMC11531087
- OpenAlex
- W4403129586
- Cited by
- 3
- References
- 101
- Citations by year
- 2025: 3
- FWCI
- 0.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (unspecified)
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
- City Research Online (City University London) (submittedVersion)
- edoc Publication server (Humboldt University of Berlin) (submittedVersion, cc-by)
- edoc Publication server (Humboldt University of Berlin) (cc-by)
- Funders
- Medical Research Council (MR/R020817/R)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
- Keywords
- escitalopram, amygdala activation, selective serotonin reuptake inhibitors, serotonin function, anxiety, healthy volunteers, prefrontal cortex, subgenual anterior cingulate cortex
- MeSH terms
- Escitalopram, Adult, Amygdala, Double-Blind Method, Female, Humans, Magnetic Resonance Imaging, Male, Citalopram, Selective Serotonin Reuptake Inhibitors, Prefrontal Cortex, Young Adult, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.